ISSN 1662-4009 (online)

ey0021.5-13 | Novel Treatments | ESPEYB21

5.13. Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model

Demuynck Benoit , Flipo Justine , Kaci Nabil , Dambkowski Carl , Paull Morgan , Muslimova Elena , Shah Bhavik P. , Legeai-Mallet Laurence

In brief: This study investigated the effect of infigratinib, a selective and orally bioavailable FGFR1-3 inhibitor, administered at different doses or according to different dosing regimens, on bone growth in a mouse model mimicking achondroplasia (Fgfr3Y367C/+). This study was partially sponsored by a grant from BridgeBio/QED Therapeutics.Commentary: Achondroplasia is one of the most common constitutional bone diseases (> 300,000 affecte...